title: Change in oxcarbazepine (Trileptal) formulation is associated with more side effects and higher blood concentrations.
authors.forename: P M
authors.initials: PM
authors.lastname: Edelbroek
authors.forename: P B
authors.initials: PB
authors.lastname: Augustijn
authors.forename: G J
authors.initials: GJ
authors.lastname: de Haan
authors.forename: M V
authors.initials: MV
authors.lastname: Rademaker
authors.forename: H H
authors.initials: HH
authors.lastname: Geesink
mesh_terms: D000927:Anticonvulsants / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D002220:Carbamazepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood / Q000737:chemistry; D004827:Epilepsy / Q000188:drug therapy; D006801:Humans; D000078330:Oxcarbazepine
chemical_list: D000927:Anticonvulsants; D002220:Carbamazepine; D000078330:Oxcarbazepine